GlassScriptPhysician profile
Catherine Forlenza
NPI 1841594546
$2,416.22
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
See the full distribution for Obstetrics & Gynecology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $793 · 2022: $1,085 · 2023: $538.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $438 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $438.14 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $1,033.82 | 2021-2023 | Injectafer |
| Abbvie INC. | $333.15 | 2021-2023 | |
| Organon LLC | $168.73 | 2021-2023 | Nexplanon |
| Astellas Pharma US INC | $144.65 | 2023 | Myrbetriq, Veozah |
| Urovant Sciences INC | $122.15 | 2021-2022 | |
| Pfizer INC. | $115.60 | 2021-2023 | |
| Exeltis, USA INC. | $101.05 | 2021-2023 | Slynd |
| Mayne Pharma Commercial LLC | $92.82 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $78.90 | 2021-2023 | |
| Therapeuticsmd, INC. | $61.60 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $58.21 | 2023 | Gemtesa |
| Myovant Sciences INC. | $52.40 | 2021-2022 | |
| Amgen INC. | $23.27 | 2021 | |
| Avion Pharmaceuticals | $17.40 | 2022 | |
| Axonics, INC. | $12.47 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Forlenza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.